Table 5.
Systolic and diastolic blood pressure in patients with prediabetes of the PLC and MO groups during the intervention.
| 0 Weeks PLC, n = 34; MO, n = 29 |
6 Weeks PLC, n = 29; MO, n = 22 |
12 Weeks PLC, n = 26; MO, n = 18 |
MIXED Model p # | Rate of Change 0 Weeks–12 Weeks a PLC, n = 26; MO, n = 18. |
||
|---|---|---|---|---|---|---|
| SBP (mmHg) | PLC | 129 ± 15 | 127 ± 187 | 128 ± 16 | 0.807 | −0.005 ± 0.099 |
| MO | 129 ± 15 | 125 ± 11 | 126 ± 11 | −0.011 ± 0.077 | ||
| NS | ||||||
| DBP (mmHg) | PLC | 79 ± 9 | 78 ± 11 | 81 ± 11 | 0.441 | 0.007 ± 0.083 |
| MO | 80 ± 9 | 76 ± 8 | 77 ± 8 | −0.031 ± 0.063 | ||
| NS | ||||||
Mean ± SD. MIXED linear model with the repeated factor “visit” and the fixed factors “treatment”, “Fat_Status” and “anti-hypertensive treatment” and the interaction “visit × treatment” and “visit × Fat_status”; p # corresponds to “visit × treatment”. a ANCOVA with the fixed factor “treatment”, the confounding factors “Fat_Status” and “anti-hypertensive treatment” and the basal value as covariate. SBP, systolic blood pressure; DBP, diastolic blood pressure; NS, not significant. PLC: placebo; MO: Moringa oleifera Lam.